Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10413349 | 0.87 | CYP3A4 (0.33) | CA2 | |
| SCHEMBL9769910 | 0.83 | CA2 (0.44) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL536089 | 0.80 | ALDH1A1 (0.44) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL1697185 | 0.79 | CA2 (0.46) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL13209347 | 0.79 | CA2 (0.41) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL304569 | 0.77 | CA2 (0.57) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL4226332 | 0.75 | CA1 (0.38) | CA2ALDH1A1TSHRTDP1NPSR1 | |
| SCHEMBL11390596 | 0.73 | CA2 (0.36) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL1535127 | 0.73 | CA2 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL27699093 | 0.73 | CA2 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0620216-B1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-0528337-B1 | New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-10-20 | — | — | EP | claimed |
| EP-1590328-B1 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110282066-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-2383573-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | Astellas Pharma Inc. (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| EP-1140836-B1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| WO-2010088000-A2 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190826-A1 | BENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| WO-1994025427-A1 | ETHANOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-10 | — | — | WO | disclosed |
| EP-0620216-A1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| EP-0593761-A1 | NEW THIOPHENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-27 | — | — | EP | disclosed |
| US-5296495-A | Antiallergens, antiinflammatory | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| WO-1993017013-A1 | QUINOLYLBENZOFURAN DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-02 | — | — | WO | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
| EP-0528337-A1 | New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991019708-A1 | NEW THIOPHENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | CYP17A1, HSD17B3, HSD3B1 | CA2 3723/4885GABRA1 3401/4885GABRB2 3282/4885 |
| US-20110282066-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | CYP17A1, KLK3, NR5A1 | CA2 3787/4885GABRA1 3450/4885GABRB2 1619/4885 |
| US-20100190826-A1 | BENZIMIDAZOLE DERIVATIVE | SHBG, SRD5A1, AR | CA2 2849/4885GABRA1 733/4885GABRB2 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.